New Tools in HCV Diagnosis, in Light of the Enhanced Awareness and the New Drugs for Treatment: SMARTube and Stimmunology

Table 3

HCV false positive rates using regular plasma versus SMARTplasma as the tested sample.

Population studied	Total samples tested	Initially reactive plasma samples	False positive plasma samples*	False positive results rate in population**	False positive SMARTplasma samples
Suspected HCV infection	683	64	8	1.1 %	0
Populations with high risk of HCV transmission	950	431	7	0.7%	0
Regular populations with unknown HCV prevalence	1445	167	10	0.7%	0
Healthy donors, low risk populations	2810	11	7	0.2%	0
Total	5888	673	32	0.5%	0

*False positive by regular serology according to the local algorithms (e.g., negative upon repeat testing).
**Percent of false positive results among total plasma samples tested in that population.